

Giuseppe Giaccone

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4800679/giuseppe-giaccone-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

542
papers

45,623
citations

106
h-index

197
g-index

575
ext. papers

51,185
ext. citations

6
avg, IF

7.05
L-index

#	Paper	IF	Citations
542	Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers. <i>Lung Cancer</i> , 2021 , 162, 23-28	5.9	2
541	Challenges in Diversity, Equity, and Inclusion in Research and Clinical Oncology. <i>Frontiers in Oncology</i> , 2021 , 11, 642112	5.3	1
540	Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 483-485	8.9	8
539	Cell-free circulating tumor DNA (cfDNA) analysis of advanced thymic epithelial tumors (TETs).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8577-8577	2.2	
538	First-time in-human study of VMD-928, an oral allosteric TrkA selective inhibitor targeting TrkA protein overexpression, in patients with solid tumors or lymphoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3081-3081	2.2	2
537	Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naïve Programmed Death-Ligand 1-Selected NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1872-1882	8.9	16
536	Thymic malignancies treated with active scanning proton beam radiation and Monte Carlo planning: early clinical experience. <i>Acta Oncologica</i> , 2021 , 60, 649-652	3.2	2
535	Lung Cancer Stage Shift as a Result of COVID-19 Lockdowns in New York City, a Brief Report. <i>Clinical Lung Cancer</i> , 2021 ,	4.9	3
534	A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 728155	5.3	3
533	Molecular predictors of response to pembrolizumab in thymic carcinoma. <i>Cell Reports Medicine</i> , 2021 , 2, 100392	18	5
532	Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer. <i>Lung Cancer</i> , 2020 , 145, 48-57	5.9	1
531	Phase I study of the Lu-DOTA-Tyr-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung 2020 , 8,		13
530	Mutant GTF2I induces cell transformation and metabolic alterations in thymic epithelial cells. <i>Cell Death and Differentiation</i> , 2020 , 27, 2263-2279	12.7	6
529	Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. <i>Cell Death and Differentiation</i> , 2020 , 27, 2143-2157	12.7	15
528	Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA) Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors?. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	1
527	Thymic epithelial tumors: From biology to treatment. <i>Cancer Treatment Reviews</i> , 2020 , 86, 102014	14.4	19
526	Safety and activity of Combined AVELumab with Axitinib in unresectable or metastatic Thymomas B3 and Thymic carcinomas: The CAVEATT study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e21114-e21114	2.2	1

525	IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e21623-e21623	2.2	6
524	Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9594-9594	2.2	0
523	Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. <i>New England Journal of Medicine</i> , 2020 , 383, 1328-1339	59.2	317
522	The International Association for the Study of Lung Cancer Thymic Tumors Staging Project: The Impact of the Eighth Edition of the Union for International Cancer Control and American Joint Committee on Cancer TNM Stage Classification of Thymic Tumors. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 436-447	8.9	21
521	Downregulation of CYLD promotes IFN- γ -mediated PD-L1 expression in thymic epithelial tumors. <i>Lung Cancer</i> , 2020 , 147, 221-228	5.9	5
520	Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis. <i>Translational Lung Cancer Research</i> , 2020 , 9, 1187-1201	4.4	7
519	Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 3187-3198	4.4	19
518	Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer. <i>Lung Cancer</i> , 2019 , 134, 108-116	5.9	12
517	Surgical Resection of SCLC: Prognostic Factors and the Tumor Microenvironment. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 914-923	8.9	39
516	Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1032-1045	8.9	19
515	Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer. <i>PLoS ONE</i> , 2019 , 14, e0212097	3.7	4
514	A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019 , 8, 247-257	4.4	8
513	Author's Reply. <i>Journal of Thoracic Oncology</i> , 2019 , 14, e243-e244	8.9	
512	The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 801-809	8.9	29
511	The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. <i>Cell Death and Differentiation</i> , 2018 , 25, 1239-1258	12.7	47
510	Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. <i>Anti-Cancer Drugs</i> , 2018 , 29, 457-465	2.4	27
509	Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. <i>Lancet Oncology</i> , 2018 , 19, 347-355	21.7	169
508	A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 81, 587-596	3.5	47

507	The Integrated Genomic Landscape of Thymic Epithelial Tumors. <i>Cancer Cell</i> , 2018 , 33, 244-258.e10	24.3	150
506	High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer. <i>Lung Cancer</i> , 2018 , 116, 38-45	5.9	15
505	Precision oncology in non-small-cell lung cancer: opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 348-349	19.4	13
504	An endogenous DNA adduct as a prognostic biomarker for hepatocarcinogenesis and its prevention by Theaphenon E in mice. <i>Hepatology</i> , 2018 , 67, 159-170	11.2	8
503	A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2018 , 8, 64	5.3	7
502	Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity. <i>European Journal of Cancer</i> , 2018 , 99, 37-48	7.5	15
501	MEK inhibitors under development for treatment of non-small-cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 17-30	5.9	38
500	The role of immune checkpoint blockade for treatment of thymic epithelial tumors— delicate balance between efficacy and side effects. <i>Mediastinum</i> , 2018 , 2, 39-39	0.5	
499	Reprint of: Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. <i>Cancer Genetics</i> , 2018 , 228-229, 131-142	2.3	3
498	Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC. <i>PLoS ONE</i> , 2018 , 13, e0208097	3.7	11
497	30 Immunotherapy in advanced NSCLC—from the tsunami of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). <i>ESMO Open</i> , 2018 , 3, e000298	6	7
496	The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1109-1121	8.9	193
495	Ganetespib for small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 103-108	5.9	1
494	A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. <i>Clinical Cancer Research</i> , 2017 , 23, 7467-7473	12.9	22
493	Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients. <i>Journal of Oncology Practice</i> , 2017 , 13, 780-783	3.1	1
492	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3484-3515	2.2	358
491	Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. <i>Cancer Genetics</i> , 2017 , 218-219, 39-50	2.3	33
490	Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. <i>Lung Cancer</i> , 2017 , 112, 195-199	5.9	7

489	Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors. <i>Cancer Research</i> , 2017 , 77, 5614-5627	10.1	19
488	The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1433-46	8.9	127
487	Lung cancer: First-line immunotherapy in lung cancer - taking the first step. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 595-6	19.4	3
486	Mutations in Latinos From the United States and Latin America. <i>Journal of Global Oncology</i> , 2016 , 2, 259-267	2.67	8
485	The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1204-1223	8.9	333
484	PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1345-1356	8.9	24
483	EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer. <i>Molecular Oncology</i> , 2016 , 10, 601-9	7.9	24
482	Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. <i>Annals of Oncology</i> , 2016 , 27, 693-9	10.3	58
481	Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. <i>Journal of Oncology Practice</i> , 2016 , 12, 83-86	3.1	16
480	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 666-680	8.9	116
479	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 453-74	8.9	106
478	Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 737-747	8.9	42
477	The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 639-650	8.9	122
476	The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 39-51	8.9	1888
475	CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma. <i>Oncotarget</i> , 2016 , 7, 29199-210	3.3	8
474	Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. <i>Translational Lung Cancer Research</i> , 2016 , 5, 720-726	4.4	24
473	Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. <i>Journal of Physical Education and Sports Management</i> , 2016 , 2, a001263	2.8	13
472	Expression of mesothelin in thymic carcinoma and its potential therapeutic significance. <i>Lung Cancer</i> , 2016 , 101, 104-110	5.9	13

471	Refining the treatment of NSCLC according to histological and molecular subtypes. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 511-26	19.4	189
470	Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1000-7	2.2	177
469	Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2100-5	2.2	113
468	Next-Generation Sequencing: Targeting Targeted Therapies. <i>Clinical Cancer Research</i> , 2015 , 21, 3584-5	12.9	9
467	Why has active immunotherapy not worked in lung cancer?. <i>Annals of Oncology</i> , 2015 , 26, 2213-20	10.3	32
466	A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. <i>European Journal of Cancer</i> , 2015 , 51, 2321-9	7.5	151
465	Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling. <i>Clinical Cancer Research</i> , 2015 , 21, 4508-13	12.9	40
464	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3488-515	2.2	363
463	Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4106-11	2.2	184
462	Alterations of immune cell subsets in relapsed, thymoma-associated minimal change disease: A case report. <i>Oncology Letters</i> , 2015 , 10, 1155-1158	2.6	10
461	Multiorgan autoimmune manifestations associated with thymoma. <i>Journal of Thoracic Oncology</i> , 2015 , 10, e5-7	8.9	9
460	Trends and Characteristics of Young Non-Small Cell Lung Cancer Patients in the United States. <i>Frontiers in Oncology</i> , 2015 , 5, 113	5.3	64
459	Novel Treatments for Thymoma and Thymic Carcinoma. <i>Frontiers in Oncology</i> , 2015 , 5, 267	5.3	1
458	Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. <i>Annals of Oncology</i> , 2015 , 26, 1421-7	10.3	191
457	Reply to A. Stenzinger et al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2824	2.2	
456	Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. <i>Lancet Oncology</i> , 2015 , 16, 177-86	21.7	160
455	LAMC2 enhances the metastatic potential of lung adenocarcinoma. <i>Cell Death and Differentiation</i> , 2015 , 22, 1341-52	12.7	59
454	High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. <i>Oncotarget</i> , 2015 , 6, 11694-703	3.3	47

453	Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. <i>Journal of the National Cancer Institute</i> , 2014 , 106, djt346	9.7	39
452	Lung cancer in 2013: Refining standard practice and admitting uncertainty. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 69-70	19.4	6
451	HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. <i>Oncogene</i> , 2014 , 33, 4867-76	9.2	35
450	Genomics-based early-phase clinical trials in oncology: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. <i>European Journal of Cancer</i> , 2014 , 50, 2747-51	7.5	6
449	Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. <i>Journal of Molecular Medicine</i> , 2014 , 92, 697-707	5.5	47
448	A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. <i>Nature Genetics</i> , 2014 , 46, 844-9	36.3	130
447	Emerging protein kinase inhibitors for non-small cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2014 , 19, 51-65	3.7	21
446	Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2014 , 15, 191-200	21.7	83
445	Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 567-71	8.9	26
444	Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 414-8	8.9	23
443	Mutations of epigenetic regulatory genes are common in thymic carcinomas. <i>Scientific Reports</i> , 2014 , 4, 7336	4.9	85
442	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014 , 5, 12472-508	3.3	301
441	CYB5A and autophagy-mediated cell death in pancreatic cancer. <i>Autophagy</i> , 2014 , 10, 697-8	10.2	5
440	A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. <i>Cancer</i> , 2014 , 120, 1145-54	6.4	100
439	Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1998-2006	27.4	1042
438	A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. <i>Clinical Cancer Research</i> , 2014 , 20, 5392-402	12.9	71
437	The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors. <i>Journal of Thoracic Oncology</i> , 2014 , 9, S81-7	8.9	71
436	The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. <i>Journal of Thoracic Oncology</i> , 2014 , 9, S65-72	8.9	243

435	Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 144-53	8.9	69
434	The ITMIG/IASLC Thymic Epithelial Tumors Staging Project: A Proposed Lymph Node Map for Thymic Epithelial Tumors in the Forthcoming 8th Edition of the TNM Classification of Malignant Tumors. <i>Journal of Thoracic Oncology</i> , 2014 , 9, S88-96	8.9	85
433	Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1609-17	8.9	46
432	The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors. <i>Journal of Thoracic Oncology</i> , 2014 , 9, S73-80	8.9	92
431	CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. <i>Journal of Clinical Investigation</i> , 2014 , 124, 3003-15	15.9	70
430	Phase II trial of sunitinib in patients with thymic epithelial tumors (TET).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7525-7525	2.2	8
429	A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7526-7526	2.2	9
428	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. <i>Lancet Oncology</i> , 2013 , 14, 981-8	21.7	402
427	Reproducibility of the WHO classification of thymomas: practical implications. <i>Lung Cancer</i> , 2013 , 79, 236-41	5.9	30
426	Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations. <i>Clinical Lung Cancer</i> , 2013 , 14, 452-6	4.9	16
425	Dacomitinib, a new therapy for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 247-53	4	28
424	From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. <i>Annals of Oncology</i> , 2013 , 24, 577-85	10.3	52
423	Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. <i>European Journal of Cancer</i> , 2013 , 49, 1808-14	7.5	8
422	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. <i>Journal of Molecular Diagnostics</i> , 2013 , 15, 447-58	5.1	340
421	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2013 , 137, 823-30	5	365
420	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 823-59	8.9	632
419	Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy. <i>Frontiers in Oncology</i> , 2013 , 3, 261	5.3	57
418	Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2601-13	6.1	24

4 ¹⁷	18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors. <i>Clinical Cancer Research</i> , 2013 , 19, 1487-93	12.9	22
4 ¹⁶	The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo. <i>Clinical Cancer Research</i> , 2013 , 19, 6777-86	12.9	22
4 ¹⁵	Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors. <i>Clinical Cancer Research</i> , 2013 , 19, 1960-71	12.9	20
4 ¹⁴	Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer. <i>Oncologist</i> , 2013 , 18, 821-2	5.7	8
4 ¹³	Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). <i>Annals of Oncology</i> , 2013 , 24, 2875-80	10.3	38
4 ¹²	Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors. <i>Cancer Science</i> , 2013 , 104, 584-9	6.9	41
4 ¹¹	A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2013 , 24, 2601-2606	10.3	101
4 ¹⁰	Characterization and management of cardiac involvement of thymic epithelial tumors. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 246-9	8.9	13
4 ⁰⁹	"Pseudocavitation" in thymic carcinoma during treatment with sunitinib. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 511-2	8.9	1
4 ⁰⁸	The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1467-73	8.9	58
4 ⁰⁷	Acute autoimmune hepatitis, myositis, and myasthenic crisis in a patient with thymoma. <i>Journal of Thoracic Oncology</i> , 2013 , 8, e87-8	8.9	7
4 ⁰⁶	Whole genome and transcriptome sequencing of a B3 thymoma. <i>PLoS ONE</i> , 2013 , 8, e60572	3.7	21
4 ⁰⁵	Custom (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies) trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7513-7513	2.2	4
4 ⁰⁴	A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8019-8019	2.2	32
4 ⁰³	Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8026-8026	2.2	16
4 ⁰²	Response to: intrapulmonary lymph node retrieval. <i>Translational Lung Cancer Research</i> , 2013 , 2, E37-8	4.4	
4 ⁰¹	Signal Transduction Inhibitors of the HER Family 2013 , 17-50		
4 ⁰⁰	Methodology for the Development of Innovative Cancer Therapies Task Force addresses methodological issues in the clinical development of innovative cancer therapies. <i>Clinical Investigation</i> , 2012 , 2, 133-138		1

399	Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. <i>Clinical Cancer Research</i> , 2012 , 18, 2099-107	12.9	94
398	Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 524-33	12.9	19
397	Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. <i>Cell Death and Disease</i> , 2012 , 3, e351	9.8	42
396	Targeted agents: how to select the winners in preclinical and early clinical studies?. <i>European Journal of Cancer</i> , 2012 , 48, 170-8	7.5	29
395	Tyrosine kinase inhibitors in lung cancer. <i>Hematology/Oncology Clinics of North America</i> , 2012 , 26, 589-605, viii	3.1	24
394	Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 3163-9	12.9	382
393	Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, E3659-67	11.5	37
392	HER2 mutations in non-small-cell lung cancer can be continually targeted. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3318-9	2.2	24
391	Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 15312-7	11.5	219
390	2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2012 , 8, 63-6	3.1	47
389	A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. <i>Annals of Oncology</i> , 2012 , 23, 968-73	10.3	104
388	Neuroendocrine ACTH-producing tumor of the thymus--experience with 12 patients over 25 years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 2223-30	5.6	49
387	EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. <i>Modern Pathology</i> , 2012 , 25, 548-55	9.8	65
386	Drug development: portals of discovery. <i>Clinical Cancer Research</i> , 2012 , 18, 23-32	12.9	32
385	Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. <i>Annals of Oncology</i> , 2012 , 23, 388-94	10.3	76
384	A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. <i>Clinical Cancer Research</i> , 2012 , 18, 2344-51	12.9	128
383	Response to crizotinib in ROS1-rearranged non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3425-6; author reply 3426	2.2	18
382	Semiautomated laser capture microdissection of lung adenocarcinoma cytology samples. <i>Acta Cytologica</i> , 2012 , 56, 622-31	3	14

381	Hepatoid carcinoma of the lung with anaplastic lymphoma kinase gene rearrangement. <i>Journal of Thoracic Oncology</i> , 2012 , 7, e29-31	8.9	17
380	Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy. <i>Current Molecular Medicine</i> , 2012 , 12, 1125-41	2.5	44
379	NUT rearrangement is uncommon in human thymic epithelial tumors. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 744-50	8.9	15
378	Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors. <i>Current Opinion in Oncology</i> , 2012 , 24, 123-9	4.2	24
377	Mesotheliomas 2012 , 319-334		
376	Phase II study of cixutumumab (IMC-A12) in thymic malignancies.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7033-7033	2.2	4
375	A phase (Ph) I/II study of belinostat (Bel) in combination with cisplatin, doxorubicin, and cyclophosphamide (PAC) in the first-line treatment of advanced or recurrent thymic malignancies.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7103-7103	2.2	4
374	Intrapulmonary lymph node retrieval: unclear benefit for aggressive pathologic dissection. <i>Translational Lung Cancer Research</i> , 2012 , 1, 230-3	4.4	5
373	Overview of pathophysiology and drug targets for non-small-cell lung cancer 2012 , 6-16		
372	Chemotherapy for thymic tumors: induction, consolidation, palliation. <i>Thoracic Surgery Clinics</i> , 2011 , 21, 107-14, viii	3.1	26
371	Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. <i>Cancer Treatment Reviews</i> , 2011 , 37, 456-64	14.4	55
370	Challenges in cancer molecular targets and therapeutics. <i>Frontiers in Oncology</i> , 2011 , 1, 4	5.3	2
369	Grand challenges in oncology. <i>Frontiers in Oncology</i> , 2011 , 1, 26	5.3	
368	Reply to M.C. Garassino et al. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3837-3837	2.2	
367	Lung cancer vaccines. <i>Cancer Journal (Sudbury, Mass)</i> , 2011 , 17, 302-8	2.2	29
366	DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens. <i>Current Drug Metabolism</i> , 2011 , 12, 956-65	3.5	7
365	Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1267-73	8.9	13
364	Population pharmacokinetic analysis of sorafenib in patients with solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2011 , 72, 294-305	3.8	100

363	Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry. <i>Oncogene</i> , 2011 , 30, 1744-52	9.2	35
362	Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 1397-403	3.5	26
361	A population-based assessment of mortality and morbidity patterns among patients with thymoma. <i>International Journal of Cancer</i> , 2011 , 128, 2688-94	7.5	49
360	Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. <i>Cell Cycle</i> , 2011 , 10, 3119-28	4.7	44
359	American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2121-7	2.2	414
358	Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors. <i>Clinical Cancer Research</i> , 2011 , 17, 2237-49	12.9	23
357	Phase I trial of SU14813 in patients with advanced solid malignancies. <i>Annals of Oncology</i> , 2011 , 22, 195-203	2.1	21
356	Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2052-9	2.2	139
355	Glioblastoma-induced inhibition of Langerhans cell differentiation from CD34(+) precursors is mediated by IL-6 but unaffected by JAK2/STAT3 inhibition. <i>Immunotherapy</i> , 2011 , 3, 1051-61	3.8	7
354	MicroRNA Expression and Outcome in Resected NSCLC Response. <i>Cancer Research</i> , 2011 , 71, 5358-5359	10.1	
353	2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3825-31	2.2	229
352	Role and relevance of TrkB mutations and expression in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 2638-45	12.9	40
351	Thymic malignancies: from clinical management to targeted therapies. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4820-7	2.2	100
350	Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. <i>Clinical Cancer Research</i> , 2011 , 17, 1190-9	12.9	63
349	Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. <i>Pharmacogenomics</i> , 2011 , 12, 159-70	2.6	58
348	A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. <i>Clinical Cancer Research</i> , 2011 , 17, 6831-9	12.9	96
347	MicroRNA expression and clinical outcome of small cell lung cancer. <i>PLoS ONE</i> , 2011 , 6, e21300	3.7	58
346	Targeting the dynamic HSP90 complex in cancer. <i>Nature Reviews Cancer</i> , 2010 , 10, 537-49	31.3	1106

345	Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC). <i>Current Drug Targets</i> , 2010 , 11, 12-28	3	13
344	Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab. <i>Journal of Clinical Oncology</i> , 2010 , 28, e507-10	2.2	36
343	Thymoma-associated paraneoplastic polymyositis. <i>Journal of Clinical Oncology</i> , 2010 , 28, e378	2.2	8
342	American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2010 , 6, 39-43	3.1	37
341	Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 13040-5	11.5	113
340	MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. <i>Cancer Research</i> , 2010 , 70, 8288-98	10.1	108
339	The role of talactoferrin alpha in the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2010 , 10, 1379-86	5.4	14
338	A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , 2010 , 16, 1915-23	12.9	64
337	Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A. <i>International Journal of Oncology</i> , 2010 , 37, 963-71	4.4	10
336	Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells. <i>Lung Cancer</i> , 2010 , 68, 154-60	5.9	31
335	Acupuncture treatment for persistent hiccups in patients with cancer. <i>Journal of Alternative and Complementary Medicine</i> , 2010 , 16, 811-6	2.4	27
334	Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. <i>European Journal of Cancer</i> , 2010 , 46, 340-7	7.5	103
333	Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. <i>European Journal of Cancer</i> , 2010 , 46, 901-11	7.5	45
332	Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 581-93	6.1	59
331	Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , 2010 , 11, 521-9	21.7	982
330	Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling. <i>Journal of Molecular Diagnostics</i> , 2010 , 12, 739-45	5.1	83
329	Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010 , 29, 95	12.8	77
328	Expression and mutational status of c-kit in thymic epithelial tumors. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1447-53	8.9	48

327	Epithelial tumors of the thymic gland are rare malignancies. Foreword. <i>Journal of Thoracic Oncology</i> , 2010 , 5, S259	8.9	3
326	Targeted therapy for advanced thymic tumors. <i>Journal of Thoracic Oncology</i> , 2010 , 5, S361-4	8.9	19
325	Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. <i>Blood</i> , 2010 , 116, 4848-58	2.2	109
324	Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010 , 878, 3187-92	3.2	1
323	Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. <i>Clinical Lung Cancer</i> , 2010 , 11, 228-37	4.9	28
322	Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells. <i>European Journal of Pharmacology</i> , 2010 , 637, 38-45	5.3	41
321	Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. <i>Cancer</i> , 2010 , 116, 4686-95	6.4	43
320	Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. <i>PLoS ONE</i> , 2010 , 5, e10630	3.7	230
319	STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. <i>Current Opinion in Investigational Drugs</i> , 2010 , 11, 1466-76		71
318	Small-molecule inhibitors of the human epidermal receptor family. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 1829-42	5.9	23
317	Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. <i>Clinical Cancer Research</i> , 2009 , 15, 5267-73	12.9	328
316	Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. <i>Annals of Oncology</i> , 2009 , 20, 1674-81	10.3	134
315	Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. <i>Annals of Oncology</i> , 2009 , 20, 182-7	10.3	42
314	Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 1815-9	8.9	26
313	Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4481-6	2.2	198
312	Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. <i>Annals of Oncology</i> , 2009 , 20, 1565-1575	10.3	18
311	An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 284-90	12.9	123
310	Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 1026-36	6.1	14

309	Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. <i>BMC Cancer</i> , 2009 , 9, 180	4.8	65
308	Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009 , 135, 467-76	4.9	9
307	The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone. <i>Trials</i> , 2009 , 10, 121	2.8	46
306	Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. <i>British Journal of Cancer</i> , 2009 , 100, 145-52	8.7	36
305	Comparative proteomics analysis of caspase-9-protein complexes in untreated and cytochrome c/dATP stimulated lysates of NSCLC cells. <i>Journal of Proteomics</i> , 2009 , 72, 575-85	3.9	21
304	American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6251-66	2.2	619
303	Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. <i>European Journal of Cancer</i> , 2009 , 45, 741-6	7.5	42
302	A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. <i>European Journal of Cancer</i> , 2009 , 45, 2519-27	7.5	12
301	Next generation oncology drug development: opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 259-65	19.4	57
300	Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling. <i>Proteome Science</i> , 2009 , 7, 34	2.6	26
299	Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 1270-3	8.9	76
298	Antiangiogenesis induced tumor cavitation in lung cancer. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 1573-5	8.9	1
297	Update on Hsp90 inhibitors in clinical trial. <i>Current Topics in Medicinal Chemistry</i> , 2009 , 9, 1479-92	3	235
296	Platinum Compounds in Lung Cancer: Current Status 2009 , 231-242		
295	Plantar erythrodysesthesia with bullous otitis externa, toxicities from sorafenib: a case report. <i>Cases Journal</i> , 2009 , 2, 6264		0
294	Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). <i>European Journal of Cancer</i> , 2008 , 44, 25-9	7.5	59
293	Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). <i>European Journal of Cancer</i> , 2008 , 44, 19-24	7.5	78
292	Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. <i>European Journal of Cancer</i> , 2008 , 44, 2178-84	7.5	32

291	Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. <i>Clinical Cancer Research</i> , 2008 , 14, 5884-92	12.9	115
290	Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. <i>Molecular Pharmacology</i> , 2008 , 73, 1290-300	4.3	130
289	Principles of Molecular Oncology 2008 ,		1
288	Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. <i>Journal of Clinical Oncology</i> , 2008 , 26, 983-94	2.2	253
287	Newer opportunities in systemic therapy of lung cancer. <i>Annals of Oncology</i> , 2008 , 19 Suppl 7, vii31-7	10.3	5
286	Src as a potential therapeutic target in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2008 , 19, 1219-1223	3	65
285	Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183. <i>Clinical Cancer Research</i> , 2008 , 14, 4186-91	12.9	5
284	Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. <i>Annals of Oncology</i> , 2008 , 19, 1605-12	10.3	74
283	Histone deacetylase inhibitors in cancer therapy. <i>Current Opinion in Oncology</i> , 2008 , 20, 639-49	4.2	89
282	Antiangiogenic therapy in nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2008 , 20, 176-82	4.2	18
281	Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. <i>PLoS ONE</i> , 2008 , 3, e0001722	3.7	84
280	Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008 , 35, 1857-67	8.8	80
279	Treatment of advanced thymoma and thymic carcinoma. <i>Current Treatment Options in Oncology</i> , 2008 , 9, 277-87	5.4	29
278	Genotype analysis of the VNTR polymorphism in the SMYD3 histone methyltransferase gene: lack of correlation with the level of histone H3 methylation in NSCLC tissues or with the risk of NSCLC. <i>International Journal of Cancer</i> , 2008 , 122, 1441-2	7.5	6
277	Bevacizumab (Avastin) 2008 , 779-812		
276	Apoptosis Pathways and New Anticancer Agents 2008 , 257-268		
275	The EGF(R) and VEGF(R) Pathways as Combined Targets for Anti-Angiogenesis Trials in Cancer Therapy 2008 , 707-715		0
274	Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain. <i>Molecular Cancer</i> , 2007 , 6, 56	42.1	20

273	The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells. <i>Molecular Cancer</i> , 2007 , 6, 73	42.1	14
272	The determination of gemcitabine and 2Pdeoxycytidine in human plasma and tissue by APCI tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 847, 142-52	3.2	41
271	Automated serum peptide profiling using novel magnetic C18 beads off-line coupled to MALDI-TOF-MS. <i>Proteomics - Clinical Applications</i> , 2007 , 1, 598-604	3.1	28
270	Immunohistochemical detection of nuclear survivin in NSCLC: a comparison of commercial antibodies. <i>Histopathology</i> , 2007 , 50, 671-5	7.3	2
269	Epidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer; a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization. <i>Histopathology</i> , 2007 , 51, 631-7	7.3	24
268	Homodimerization antagonizes nuclear export of survivin. <i>Traffic</i> , 2007 , 8, 1495-502	5.7	35
267	Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: a small molecule Smac mimic sensitizes for chemotherapy-induced apoptosis by enhancing caspase-3 activation. <i>Experimental Cell Research</i> , 2007 , 313, 1215-24	4.2	39
266	The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. <i>European Radiology</i> , 2007 , 17, 1700-13	8	69
265	Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 442-50	9.7	512
264	Global histone modifications predict prognosis of resected non small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4358-64	2.2	232
263	Angiogenesis inhibitors. Drug selectivity and target specificity. <i>Current Pharmaceutical Design</i> , 2007 , 13, 2795-809	3.3	37
262	A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183. <i>Clinical Cancer Research</i> , 2007 , 13, 3906-12	12.9	24
261	A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2007 , 13, 3642-51	12.9	46
260	The potential of antiangiogenic therapy in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 1961-70	12.9	57
259	Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 1046-53	6.1	45
258	Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor. <i>Clinical and Developmental Immunology</i> , 2007 , 2007, 17315		18
257	Genetic Heterogeneity in Patients with Multiple Neoplastic Lung Lesions: A Report of Three Cases. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 12-21	8.9	14
256	A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer. <i>Anti-Cancer Drugs</i> , 2007 , 18, 219-25	2.4	42

255	Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). <i>European Journal of Cancer</i> , 2007 , 43, 114-21	7.5	144
254	TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 2103-12	6.1	103
253	EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens. <i>Analytical Cellular Pathology</i> , 2007 , 29, 257-64	3.4	40
252	Genetic Heterogeneity in Patients with Multiple Neoplastic Lung Lesions: A Report of Three Cases. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 12-21	8.9	25
251	How should we analyse FDG PET studies for monitoring tumour response?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006 , 33 Suppl 1, 16-21	8.8	54
250	Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006 , 58, 509-16	3.5	14
249	Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. <i>BMC Cancer</i> , 2006 , 6, 129	4.8	97
248	TUCAN/CARDINAL/CARD8 and apoptosis resistance in non-small cell lung cancer cells. <i>BMC Cancer</i> , 2006 , 6, 166	4.8	10
247	Response to erlotinib in first-line treatment of non-small-cell lung cancer in a white male smoker with squamous-cell histology. <i>Clinical Lung Cancer</i> , 2006 , 8, 214-6	4.9	11
246	Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidylinositol-3 kinase pathways in non-small cell lung cancer cells. <i>International Journal of Cancer</i> , 2006 , 118, 209-14	7.5	130
245	Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. <i>Clinical Cancer Research</i> , 2006 , 12, 6049-55	12.9	173
244	Iron absorption during epoetin alfa therapy for chemotherapy-associated anaemia. <i>Cancer Investigation</i> , 2006 , 24, 562-6	2.1	3
243	Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres. <i>Molecular Biology of the Cell</i> , 2006 , 17, 1897-909	3.5	65
242	Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data. <i>Oncologist</i> , 2006 , 11, 197-205	5.7	9
241	Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluorouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. <i>Annals of Oncology</i> , 2006 , 17, 35-42	10.3	42
240	A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. <i>Clinical Cancer Research</i> , 2006 , 12, 6064-72	12.9	215
239	Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level. <i>Oncologist</i> , 2006 , 11, 206-16	5.7	16
238	Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1435-42	2.2	60

237	Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity. <i>Clinical Cancer Research</i> , 2006 , 12, 1760-7	12.9	20
236	Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1612-9	2.2	181
235	Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. <i>Annals of Oncology</i> , 2006 , 17, 1698-704	10.3	132
234	Analysis of deoxycytidine accumulation in gemcitabine treated patients. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2006 , 25, 1225-32	1.4	3
233	Keynote comment: are large-scale cancer-genomics projects ready to use?. <i>Lancet Oncology</i> , 2006 , 7, 190-1	21.7	2
232	Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984). <i>European Journal of Cancer</i> , 2006 , 42, 1399-406	7.5	17
231	Quality assurance of thoracic radiotherapy in EORTC 08941: a randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy. <i>European Journal of Cancer</i> , 2006 , 42, 1391-8	7.5	10
230	Biology and management of malignant pleural mesothelioma. <i>European Journal of Cancer</i> , 2006 , 42, 2706-14	5.4	56
229	Expression and localization of inhibitor of apoptosis proteins in normal human tissues. <i>Human Pathology</i> , 2006 , 37, 78-86	3.7	55
228	Mesotheliomas 2006 , 279-292		
227	Systemic treatment of malignant thymoma: a decade experience at a single institution. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006 , 29, 336-44	2.7	36
226	Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma. <i>Journal of Thoracic Oncology</i> , 2006 , 1, S32-S36	8.9	13
225	Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma. <i>Journal of Thoracic Oncology</i> , 2006 , 1, S32-S36	8.9	16
224	Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 2905-13	6.1	100
223	Subcellular localization and nucleocytoplasmic transport of the chromosomal passenger proteins before nuclear envelope breakdown. <i>Oncogene</i> , 2006 , 25, 4867-79	9.2	32
222	Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8081-92	2.2	551
221	Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial. <i>European Journal of Cancer</i> , 2005 , 41, 1560-9	7.5	39
220	Cell death independent of caspases: a review. <i>Clinical Cancer Research</i> , 2005 , 11, 3155-62	12.9	719

219	A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). <i>Lung Cancer</i> , 2005 , 50, 91-6	5.9	38
218	Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology?. <i>Current Opinion in Oncology</i> , 2005 , 17, 392-6	4.2	17
217	Treatment of malignant thymoma. <i>Current Opinion in Oncology</i> , 2005 , 17, 140-6	4.2	35
216	Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11. <i>British Journal of Cancer</i> , 2005 , 92, 882-7	8.7	16
215	FANCD2 expression in advanced non-small-cell lung cancer and response to platinum-based chemotherapy. <i>Clinical Lung Cancer</i> , 2005 , 6, 250-4	4.9	12
214	Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies. <i>International Journal of Cancer</i> , 2005 , 117, 883-8	7.5	133
213	Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. <i>Cancer</i> , 2005 , 104, 1794-807	6.4	140
212	Morbidity and mortality in the surgery arm of EORTC 08941 trial. <i>European Respiratory Journal</i> , 2005 , 26, 192-7	13.6	74
211	HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. <i>Annals of Oncology</i> , 2005 , 16, 538-48	10.3	39
210	Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3235-42	2.2	183
209	Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. <i>Clinical Cancer Research</i> , 2005 , 11, 6240-6	12.9	41
208	Medical treatment of non-small-cell lung cancer. <i>Annals of Oncology</i> , 2005 , 16 Suppl 2, ii229-32	10.3	5
207	Targeting HER1/EGFR in cancer therapy: experience with erlotinib. <i>Future Oncology</i> , 2005 , 1, 449-60	3.6	17
206	Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6881-9	2.2	527
205	EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer. <i>Nature Clinical Practice Oncology</i> , 2005 , 2, 296-7		13
204	Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule. <i>British Journal of Cancer</i> , 2005 , 92, 1636-43	8.7	14
203	EGFR inhibitors: what have we learned from the treatment of lung cancer?. <i>Nature Clinical Practice Oncology</i> , 2005 , 2, 554-61		69
202	Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. <i>Annals of Oncology</i> , 2005 , 16, 1695-701	10.3	48

201	Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). <i>Journal of Clinical Oncology</i> , 2005 , 23, 6854-64	2.2	179
200	Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours. <i>Journal of Clinical Pathology</i> , 2005 , 58, 695-9	3.9	15
199	Identification of multiple nuclear export sequences in Fanconi anemia group A protein that contribute to CRM1-dependent nuclear export. <i>Human Molecular Genetics</i> , 2005 , 14, 1271-81	5.6	29
198	Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. <i>Molecular Pharmacology</i> , 2005 , 68, 502-10	4.3	92
197	Lung cancer. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005 , 22, 413-42		
196	Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. <i>Cancer Research</i> , 2004 , 64, 27-30	10.1	190
195	Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer. <i>Annals of Oncology</i> , 2004 , 15, 484-8	10.3	16
194	Twenty-five years of treating advanced NSCLC: what have we achieved?. <i>Annals of Oncology</i> , 2004 , 15 Suppl 4, iv81-3	10.3	11
193	The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. <i>Clinical Cancer Research</i> , 2004 , 10, 4072-6	12.9	13
192	Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. <i>Annals of Oncology</i> , 2004 , 15, 230-5	10.3	28
191	Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver. <i>Annals of Oncology</i> , 2004 , 15, 59-63	10.3	38
190	Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma. <i>Cancer Research</i> , 2004 , 64, 5753-9	10.1	55
189	Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2004 , 15, 831-8	10.3	42
188	Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. <i>Journal of Clinical Oncology</i> , 2004 , 22, 785-94	2.2	1508
187	Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2004 , 15, 1654-60	10.3	68
186	Cancer of the esophagus and gastric cardia: recent advances. <i>Ecological Management and Restoration</i> , 2004 , 17, 10-26	3	54
185	Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA. <i>Cancer Gene Therapy</i> , 2004 , 11, 539-46	5.4	28
184	The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression. <i>Oncogene</i> , 2004 , 23, 9102-10	9.2	29

183	Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL. <i>British Journal of Cancer</i> , 2004 , 91, 171-7	8.7	26
182	Clinical potential of proteasome inhibition in solid tumours. <i>European Journal of Cancer, Supplement</i> , 2004 , 2, 25-28	1.6	3
181	Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. <i>Journal of Clinical Oncology</i> , 2004 , 22, 777-84	2.2	1496
180	The immunoregulatory role of CD1d-restricted natural killer T cells in disease. <i>Clinical Immunology</i> , 2004 , 112, 8-23	9	95
179	Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. <i>European Journal of Cancer</i> , 2004 , 40, 667-72	7.5	27
178	Nuclear shuttling and TRAF2-mediated retention in the cytoplasm regulate the subcellular localization of cIAP1 and cIAP2. <i>Experimental Cell Research</i> , 2004 , 298, 535-48	4.2	32
177	Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. <i>Lung Cancer</i> , 2004 , 43, 63-9	5.9	107
176	The role of gefitinib in lung cancer treatment. <i>Clinical Cancer Research</i> , 2004 , 10, 4233s-4237s	12.9	48
175	Molecular Pathways of Drug Resistance 2004 , 463-489		1
174	Subcellular localization of CrmA: identification of a novel leucine-rich nuclear export signal conserved in anti-apoptotic serpins. <i>Biochemical Journal</i> , 2003 , 373, 251-9	3.8	14
173	Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydropyridine (molar ratio 1:0.4:1) in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2003 , 52, 1-12	3.5	39
172	Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2237-46	2.2	2543
171	Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 1453-61	9.7	449
170	Ongoing and future trials of biologic therapies in lung cancer. <i>Lung Cancer</i> , 2003 , 41 Suppl 1, S175-86	5.9	18
169	Lung cancer. Introduction. <i>Lung Cancer</i> , 2003 , 41 Suppl 1, S1	5.9	219
168	Cisplatin triggers apoptotic or nonapoptotic cell death in Fanconi anemia lymphoblasts in a concentration-dependent manner. <i>Experimental Cell Research</i> , 2003 , 286, 381-95	4.2	17
167	The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). <i>European Journal of Cancer</i> , 2003 , 39, 353-7	7.5	59
166	Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965). <i>European Journal of Cancer</i> , 2003 , 39, 1271-6	7.5	101

165	Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958). <i>European Journal of Cancer</i> , 2003 , 39, 1416-22	7.5	50
164	Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923). <i>Annals of Oncology</i> , 2003 , 14, 248-57	10.3	21
163	Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3909-17	2.2	303
162	Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. <i>Oncologist</i> , 2003 , 8, 576-86	5.7	58
161	Signal transduction modulators for cancer therapy: from promise to practice?. <i>Oncologist</i> , 2003 , 8, 210-35	7	4
160	Travoprost: a potent ocular hypotensive agent. <i>Drugs of Today</i> , 2003 , 39, 61-74		30
159	Lung cancer. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003 , 21, 445-83		5
158	Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. <i>Clinical Cancer Research</i> , 2003 , 9, 2316-26	12.9	206
157	Polarization of V α 24+ V β 11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells. <i>Cancer Research</i> , 2003 , 63, 4101-6	10.1	56
156	Endothelial dysfunction in antiangiogenesis-associated thrombosis. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3042; author reply 3042-3	2.2	19
155	Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1657-67	2.2	216
154	Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975. <i>Seminars in Oncology</i> , 2002 , 29, 47-9	5.5	11
153	Population pharmacokinetics of the novel anticancer agent KR7000. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 49, 287-93	3.5	29
152	Novel approaches to the treatment of non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2002 , 41, 57-77	7	29
151	Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. <i>British Journal of Dermatology</i> , 2002 , 147, 598-601	4	143
150	Clinical impact of novel treatment strategies. <i>Oncogene</i> , 2002 , 21, 6970-81	9.2	39
149	A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma. <i>British Journal of Cancer</i> , 2002 , 86, 1230-4	8.7	21
148	Selective decrease in circulating V α 24+V β 11+ NKT cells during HIV type 1 infection. <i>Journal of Immunology</i> , 2002 , 168, 1490-5	5.3	134

147	Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4434-9	2.2	214
146	Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1657-1667	2.2	116
145	Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3947-55	2.2	94
144	CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. <i>Experimental Cell Research</i> , 2002 , 275, 44-53	4.2	125
143	Natural Killer T cells. <i>Lancet Oncology, The</i> , 2002 , 3, 574	21.7	7
142	A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma. <i>European Journal of Cancer</i> , 2002 , 38, 779-83	7.5	31
141	Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. <i>European Journal of Cancer</i> , 2002 , 38, 1212-7	7.5	67
140	The role of new agents in the treatment of non-small cell lung cancer. <i>European Journal of Cancer</i> , 2002 , 38, 2347-61	7.5	26
139	Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. <i>Clinical Cancer Research</i> , 2002 , 8, 596-606	12.9	73
138	Apoptosis: target of cancer therapy. <i>Clinical Cancer Research</i> , 2002 , 8, 2024-34	12.9	168
137	A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. <i>Clinical Cancer Research</i> , 2002 , 8, 3702-9	12.9	375
136	Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. <i>Journal of Immunological Methods</i> , 2001 , 247, 61-72	2.5	86
135	Thymoma: update for the new millennium. <i>Oncologist</i> , 2001 , 6, 239-46	5.7	70
134	Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy. <i>British Journal of Cancer</i> , 2001 , 85, 1456-61	8.7	15
133	Exercise-induced spontaneous hemothorax insinuates trauma; yet unmasks a latent disorder. <i>Netherlands Journal of Medicine</i> , 2001 , 59, 292-4	0.5	4
132	Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. <i>Clinical Immunology</i> , 2001 , 100, 144-8	9	225
131	Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2001 , 32, 117-28	5.9	46
130	Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling. <i>Lung Cancer</i> , 2001 , 33, 267-75	5.9	11

129	State of the art in systemic treatment of lung cancer. <i>European Journal of Cancer</i> , 2001 , 37 Suppl 7, S99-114	11.4	3
128	Chemotherapy for non-small-cell lung cancer. <i>Lancet, The</i> , 2001 , 358, 1271-2	4.0	2
127	Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. <i>Annals of Oncology</i> , 2001 , 12, 1359-68	10.3	82
126	5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients. <i>Annals of Oncology</i> , 2001 , 12, 209-16	10.3	52
125	A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients. <i>Annals of Oncology</i> , 2001 , 12, 1567-73	10.3	7
124	Fluorouracil (5FU) pharmacokinetics in 5FU prodrug formulations with a dihydropyrimidine dehydrogenase inhibitor. <i>Journal of Clinical Oncology</i> , 2001 , 19, 4267-9	2.2	9
123	Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2001 , 12, 799-805	10.3	82
122	Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3400-8	2.2	184
121	Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients. <i>Anti-Cancer Drugs</i> , 2000 , 11, 687-94	2.4	8
120	Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. <i>Annals of Oncology</i> , 2000 , 11, 385-91	10.3	125
119	A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2000 , 11, 109-12	10.3	47
118	Caelyx in malignant mesothelioma: a phase II EORTC study. <i>Annals of Oncology</i> , 2000 , 11, 697-700	10.3	49
117	The multilayered postconfluent cell culture as a model for drug screening. <i>Critical Reviews in Oncology/Hematology</i> , 2000 , 36, 141-57	7	62
116	Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. <i>British Journal of Cancer</i> , 2000 , 83, 1069-76	8.7	67
115	Human natural killer T cells acquire a memory-activated phenotype before birth. <i>Blood</i> , 2000 , 95, 2440-2442	11.4	89
114	Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver. <i>Oncology</i> , 2000 , 59, 89-97	3.6	13
113	Hepatic arterial 5-fluorouracil in patients with liver metastases of colorectal cancer: single-centre experience in 145 patients. <i>Annals of Oncology</i> , 2000 , 11, 1563-70	10.3	17
112	Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients. <i>Annals of Oncology</i> , 2000 , 11, 965-70	10.3	54

111	Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3722-30	2.2	108
110	Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). <i>Journal of Clinical Oncology</i> , 2000 , 18, 2658-64	2.2	131
109	Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2772-9	2.2	150
108	Treatment of thymoma and thymic carcinoma. <i>Annals of Oncology</i> , 2000 , 11 Suppl 3, 245-6	10.3	5
107	A bone biopsy is mandatory in the optimal management of bone lesions in patients with a long-term history of malignancy of the breast. <i>Netherlands Journal of Medicine</i> , 2000 , 56, 223-8	0.5	
106	Severe acute lung injury induced by gemcitabine. <i>Netherlands Journal of Medicine</i> , 2000 , 56, 232-5	0.5	24
105	Synergistic effect of KRN7000 with interleukin-15, -7, and -2 on the expansion of human V alpha 24+V beta 11+ T cells in vitro. <i>Human Immunology</i> , 2000 , 61, 357-65	2.3	30
104	Cross-resistance in the 2P2Pdifluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. <i>European Journal of Cancer</i> , 2000 , 36, 1974-83	7.5	37
103	Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours. <i>European Journal of Cancer</i> , 2000 , 36, 2420-9	7.5	26
102	Clinical perspectives on platinum resistance. <i>Drugs</i> , 2000 , 59 Suppl 4, 9-17; discussion 37-8	12.1	261
101	Human natural killer T cells acquire a memory-activated phenotype before birth. <i>Blood</i> , 2000 , 95, 2440-2442	4.4	6
100	Treatment of thymoma and thymic carcinoma. <i>Annals of Oncology</i> , 2000 , 11, 245-246	10.3	2
99	Pancreaticobiliary cancer: The future aspects of medical oncology. <i>Annals of Oncology</i> , 1999 , 10, S296-S299	9.3	6
98	Current chemotherapeutic possibilities in pancreaticobiliary cancer. <i>Annals of Oncology</i> , 1999 , 10, S157-S161	9.3	16
97	p53 and chemosensitivity. <i>Annals of Oncology</i> , 1999 , 10, 1011-21	10.3	130
96	Effects of alpha-galactosylceramide (KRN7000), interleukin-12 and interleukin-7 on phenotype and cytokine profile of human Valpha24+ Vbeta11+ T cells. <i>Immunology</i> , 1999 , 98, 557-63	7.8	28
95	A phase II study of gemcitabine in patients with malignant pleural mesothelioma. <i>Cancer</i> , 1999 , 85, 2577-2582	4.5	113
94	Second-line chemotherapy and its evaluation in small cell lung cancer. <i>Cancer Treatment Reviews</i> , 1999 , 25, 199-206	14.4	54

93	10th Conference on DNA Topoisomerases in therapy. <i>Drug Resistance Updates</i> , 1999 , 2, 347-350	23.2	2
92	Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. <i>European Journal of Cancer</i> , 1999 , 35, 796-807	7.5	121
91	The cost-effectiveness of paclitaxel (Taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysis. <i>Anti-Cancer Drugs</i> , 1999 , 10, 605-15	2.4	17
90	Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2190-7	2.2	129
89	Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening. <i>British Journal of Cancer</i> , 1998 , 78, 1586-93	8.7	8
88	Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. <i>British Journal of Cancer</i> , 1998 , 77, 621-6	8.7	155
87	Clinical resistance to topoisomerase-targeted drugs. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1998 , 1400, 275-88		38
86	Are platinum compounds mandatory in the treatment of metastatic non-small cell lung cancer?. <i>European Journal of Cancer</i> , 1998 , 34, 1993-9	7.5	9
85	Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens. <i>Clinical Drug Investigation</i> , 1998 , 15, 327-35	3.2	8
84	Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study. <i>Radiotherapy and Oncology</i> , 1998 , 46, 29-32	5.3	75
83	CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. <i>British Journal of Cancer</i> , 1998 , 77, 359-65	8.7	51
82	Determinants of CPT-11 and SN-38 activities in human lung cancer cells. <i>British Journal of Cancer</i> , 1998 , 77, 2171-6	8.7	69
81	Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. <i>Journal of Clinical Oncology</i> , 1998 , 16, 145-52	2.2	423
80	Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 1998 , 16, 2133-41	2.2	237
79	Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer. <i>Annals of Oncology</i> , 1997 , 8, 957-62	10.3	14
78	Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. <i>Journal of Clinical Oncology</i> , 1997 , 15, 317-29	2.2	152
77	Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. <i>European Journal of Cancer</i> , 1997 , 33, 1759-66	7.5	45
76	Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group. <i>European Journal of Cancer</i> , 1997 , 33, 2211-5	7.5	45

75	Chemotherapy. <i>Lancet, The</i> , 1997 , 349 Suppl 2, S117-9	4.0	10
74	Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study. <i>Journal of Clinical Oncology</i> , 1997 , 15, 2840-9	2.2	106
73	Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 1997 , 15, 2090-6	2.2	372
72	CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. <i>International Journal of Cancer</i> , 1997 , 70, 335-40	7.5	88
71	Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. <i>International Journal of Cancer</i> , 1997 , 71, 787-95	7.5	70
70	p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. <i>British Journal of Cancer</i> , 1996 , 74, 63-8	8.7	78
69	Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues. <i>Annals of Oncology</i> , 1996 , 7, 625-30	10.3	40
68	Oncogenes and antioncogenes in lung tumorigenesis. <i>Chest</i> , 1996 , 109, 130S-134S	5.3	29
67	Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial. <i>European Journal of Cancer</i> , 1996 , 32A, 1498-503	7.5	27
66	Ongoing clinical trials in lung cancer. <i>European Journal of Surgical Oncology</i> , 1996 , 22, 4-9	3.6	
65	Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 1996 , 14, 814-20	2.2	173
64	Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 1996 , 14, 127-34	2.2	23
63	Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative group. <i>Annals of Oncology</i> , 1996 , 7, 637-9	10.3	8
62	Treatment of metastatic non-small cell lung cancer. <i>Current Opinion in Oncology</i> , 1996 , 8, 120-5	4.2	19
61	Drug Resistance. <i>Oncologist</i> , 1996 , 1, 82-87	5.7	50
60	MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs. <i>International Journal of Cancer</i> , 1996 , 66, 760-7	7.5	45
59	Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. <i>British Journal of Cancer</i> , 1996 , 74, 961-3	8.7	75
58	Differential expression of the c-kit proto-oncogene in germ cell tumours. <i>Journal of Pathology</i> , 1995 , 177, 253-8	9.4	125

57	Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1995 , 1264, 337-46		55
56	Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 1995 , 13, 660-5	2.2	57
55	Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. <i>Journal of the National Cancer Institute</i> , 1995 , 87, 1230-7	9.7	203
54	Effects of suramin on human lung cancer cell lines. <i>European Journal of Cancer</i> , 1995 , 31A, 244-51	7.5	12
53	MDR1/P-glycoprotein expression in colorectal cancer. <i>European Journal of Cancer</i> , 1995 , 31A, 1291-4	7.5	44
52	Multidrug resistance in breast cancer: mechanisms, strategies. <i>European Journal of Cancer</i> , 1995 , 31A Suppl 7, S15-7	7.5	11
51	New drugs in non-small cell lung cancer. An overview. <i>Lung Cancer</i> , 1995 , 12 Suppl 1, S155-62	5.9	14
50	Multidrug resistance proteins and other drug transport-related resistance to natural product agents. <i>Current Opinion in Oncology</i> , 1995 , 7, 532-40	4.2	64
49	Prognostic relevance of P-glycoprotein expression in breast cancer. <i>Annals of Oncology</i> , 1995 , 6, 679-85	10.3	62
48	DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?. <i>British Journal of Cancer</i> , 1995 , 72, 917-21	8.7	56
47	MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: alterations in cellular pharmacokinetics and in pattern of cross-resistance. <i>International Journal of Cancer</i> , 1995 , 62, 84-9	7.5	36
46	A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. <i>Chest</i> , 1994 , 106, 320S-323S	5.3	184
45	Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures. <i>Biochemical Pharmacology</i> , 1994 , 48, 1145-54	6	15
44	Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. <i>Biochemical Pharmacology</i> , 1994 , 47, 1325-32	6	33
43	Complete remission of metastatic colorectal cancer: a pitfall in a multidrug resistance reversal trial. <i>Lancet, The</i> , 1994 , 343, 1648-9	4.0	6
42	In vitro sequence-dependent synergistic effect of suramin and camptothecin. <i>European Journal of Cancer</i> , 1994 , 30A, 1670-4	7.5	2
41	A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. <i>Chest</i> , 1994 , 106, 320S-323S	5.3	106
40	Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures. <i>European Journal of Cancer</i> , 1993 , 29A, 1566-73	7.5	33

39	Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 1993 , 11, 1230-40	2.2	124
38	Cortisol is transported by the multidrug resistance gene product P-glycoprotein. <i>British Journal of Cancer</i> , 1993 , 67, 284-9	8.7	114
37	Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell lung cancer in a randomised phase II study. The EORTC Lung Cancer Cooperative group. <i>European Journal of Cancer</i> , 1992 , 28, 96-100	7.5	11
36	The differential diagnosis of primary lung cancer: inter-observer agreement and contribution of specific diagnostic procedures. <i>Journal of Clinical Epidemiology</i> , 1992 , 45, 827-33	5.7	5
35	Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative Group. <i>European Journal of Cancer</i> , 1992 , 28A, 1667-70	7.5	13
34	Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 1992 , 10, 824-8	2.2	58
33	Phase II study of ACNU as second-line treatment in small-cell lung cancer. EORTC Lung Cancer Cooperative Group. <i>Cancer Chemotherapy and Pharmacology</i> , 1992 , 29, 409-11	3.5	7
32	Increased expression of differentiation markers can accompany laminin-induced attachment of small cell lung cancer cells. <i>British Journal of Cancer</i> , 1992 , 66, 488-95	8.7	8
31	Growth, morphology and chemosensitivity studies on postconfluent cells cultured in V-bottomed microtiter plates. <i>British Journal of Cancer</i> , 1992 , 66, 660-5	8.7	25
30	Phase II study of ACNU in non-small-cell lung cancer: EORTC study 08872. <i>Cancer Chemotherapy and Pharmacology</i> , 1991 , 28, 145-6	3.5	6
29	Mitomycin C, teniposide, and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. <i>Cancer Chemotherapy and Pharmacology</i> , 1991 , 28, 147-9	3.5	
28	Multidrug resistance from the clinical point of view. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 1481-6		34
27	Pilot study of teniposide in combination chemotherapy for small cell lung cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 141-3		1
26	Multimodality treatment of malignant germ cell tumours of the mediastinum. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 273-7		14
25	Bepiridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 739-44		25
24	Cisplatin and teniposide chemotherapy for advanced non-small cell lung cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 1104-6		1
23	Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 1627-9		46
22	Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990 , 87, 6698-702	11.5	209

21	4PEPI-doxorubicin in advanced lung cancer. A phase II trial. <i>Investigational New Drugs</i> , 1990 , 8, 393-6	4.3	7
20	Effects of tumor necrosis factor, alone or in combination with topoisomerase-II-targeted drugs, on human lung cancer cell lines. <i>International Journal of Cancer</i> , 1990 , 46, 326-9	7.5	17
19	Doxorubicin and etoposide in the treatment of advanced measurable breast cancer. <i>Oncology</i> , 1990 , 47, 105-8	3.6	1
18	Phase II Study of Divided-Dose Vinblastine in Advanced Cancer Patients. <i>Tumori</i> , 1989 , 75, 248-251	1.7	2
17	Second line chemotherapy in small cell lung cancer. <i>Lung Cancer</i> , 1989 , 5, 207-213	5.9	19
16	The role of thoracic radiation therapy in small cell carcinoma of the lung: a consensus report. <i>Lung Cancer</i> , 1989 , 5, 135-138	5.9	16
15	Phase II study of 9-hydroxy-2-methyl-ellipticinium acetate (ellipticinium) in patients with advanced carcinoma of the lung. EORTC Lung Cancer Cooperative Group. <i>European Journal of Cancer & Clinical Oncology</i> , 1989 , 25, 909-10		9
14	Identification of new drugs in pretreated patients with small cell lung cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1989 , 25, 411-3		11
13	Phase II study of divided-dose vinblastine in advanced breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1988 , 21, 65-7	3.5	3
12	Teniposide (VM26): an effective treatment for brain metastases of small cell carcinoma of the lung. <i>European Journal of Cancer & Clinical Oncology</i> , 1988 , 24, 629-31		21
11	Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. <i>Journal of Clinical Oncology</i> , 1988 , 6, 1264-70	2.2	113
10	Mitomycin C, vinblastine and cis-platin. An active regimen for advanced non-small cell lung cancer. <i>British Journal of Cancer</i> , 1987 , 56, 475-8	8.7	11
9	Bone marrow evaluation in small cell carcinoma of the lung. <i>Acta Oncologica</i> , 1987 , 26, 185-8	3.2	9
8	Reinduction chemotherapy in small cell lung cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1987 , 23, 1697-9		84
7	4PDeoxydoxorubicin, an inactive drug in small cell lung cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1987 , 23, 1407-8		4
6	Thymomas. A review of 169 cases, with particular reference to results of surgical treatment. <i>Cancer</i> , 1986 , 58, 765-76	6.4	145
5	Stevens-Johnson Syndrome and Fatal Pulmonary Toxicity to Combination Chemotherapy Containing Bleomycin: A Case Report. <i>Tumori</i> , 1986 , 72, 331-333	1.7	11
4	Chest irradiation as an attempt to improve the response after induction chemotherapy in small cell lung carcinoma. <i>Acta Radiologica Oncology</i> , 1985 , 24, 475-9		4

3	Disorders of serum electrolytes and renal function in patients treated with cis-platinum on an outpatient basis. <i>European Journal of Cancer & Clinical Oncology</i> , 1985 , 21, 433-7		20
2	Comparison of Methylprednisolone and Metoclopramide in the Prophylactic Treatment of CIS-Platin-Induced Nausea and Vomiting. <i>Tumori</i> , 1984 , 70, 237-241	1.7	4
1	Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone. <i>Lancet, The</i> , 1984 , 2, 1336-7	40	33